inclusion criteria: - age: 18 to 74 years (at the time of informed consent) - gender: male or female - patients with sars-cov-2-positive nasopharyngeal swab by rt-pcr test with non-severe presentation upon admission to clinical trial site hospitals or trial-supervised quarantine facilities or under trial -supervised home isolation; - for premenopausal female patients, patients who have been confirmed to be negative on a pregnancy test before administration of the study drug; - patients who understand the contents of this study and can provide written consent by themselves without assistance, or as appropriate with their assent and consent of their parents

inclusion criteria: - age: 18 to 74 years (at the time of informed consent) - gender: male or female - patients with sars-cov-2-positive nasopharyngeal swab by rt-pcr test with non-severe presentation upon admission to clinical trial site hospitals or trial-supervised quarantine facilities or under trial -supervised home isolation; - for premenopausal female patients, patients who have been confirmed to be negative on a pregnancy test before administration of the study drug; - patients who understand the contents of this study and can provide written consent by themselves without assistance, or as appropriate with their assent and consent of their parents